New Drug Combination Shown to be Effective for Patients with Advanced Ovarian Cancer
Ovarian cancer is the most lethal gynecologic malignancy. Novel approaches for relapsed ovarian cancer are necessary to improve survival.
The Women’s Cancer Research Foundation (WCRF) annually publishes and funds numerous clinical studies on breast and gynecologic (ovarian, endometrial, and cervical) cancers. The WCRF’s oncology experts work tirelessly with the belief that each new clinical study has the potential to fundamentally improve the outcomes of patients diagnosed with breast and gynecologic cancers.